alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › tirzepatide

tirzepatide

4 studies tagged tirzepatide, dated 2024-07-11 to 2026-02-25. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort study 2026-02-25
  2. Unveiling Tirzepatide's Therapeutic Spectrum: A Dual GIP/GLP-1 Agonist Targeting Metabolic, Neurological, and Cardiovascular Health 2025-10-01
  3. A novel therapeutic prospect: a dual-acting tirzepatide for Alzheimer's disease 2025-07-22

Studies

4 studies carry this tag.

Date range

2024 to 2026

Top journals

  • European journal of pharmacology 1
  • International journal of endocrinology 1
  • Journal of diabetes and its complications 1
  • Peptides 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort study

    ✓ Peer-reviewed alzhub usefulness score 79 out of 100. Journal of diabetes and its complications 2026-02-25 Drug development

    A total of 290,606 patients initiated semaglutide and 44,471 initiated tirzepatide.

  2. Unveiling Tirzepatide's Therapeutic Spectrum: A Dual GIP/GLP-1 Agonist Targeting Metabolic, Neurological, and Cardiovascular Health

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. International journal of endocrinology 2025-10-01 Drug development

    Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a groundbreaking treatment for Type 2 diabetes mellitus (T2DM) and obesity.

  3. A novel therapeutic prospect: a dual-acting tirzepatide for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. European journal of pharmacology 2025-07-22 Drug development

    Alzheimer's disease (AD), the leading cause of dementia, involves microglial activation, pro-inflammatory cytokine release, and impaired insulin signaling via insulin receptor substrate 1 (IRS-1) inhibition.

  4. Tirzepatide shows neuroprotective effects via regulating brain glucose metabolism in APP/PS1 mice

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Peptides 2024-07-11 Drug development

    Tirzepatide (LY3298176), a GLP-1 and GIP receptor agonist, is fatty-acid-modified and 39-amino acid linear peptide, which ameliorates learning and memory impairment in diabetic rats.

All topic tags with their study counts